Mylan Inks $264M Deal Ending EpiPen Class Price-Hike Suit

By Bonnie Eslinger · February 28, 2022, 9:19 PM EST

Health care company Viatris — formerly known as Mylan — said Monday that it has agreed to a $264 million settlement to resolve class action claims that it conspired with Pfizer Inc....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Recent Articles By Bonnie

June 28, 2024
Texas Justices Back Ban On Gender Affirming Care For Minors
June 28, 2024
Jury Convicts Seattle Doctor In NBA Health Fraud Case
May 17, 2024
Pfizer Unit Wins $107.5M Patent Verdict Against AstraZeneca
March 22, 2024
Expert's Sanctions Off Limits In SEC's 'Shadow Trading' Trial
March 11, 2024
Acadia Investors Get Class Cert. In Suit Over Parkinson's Drug
March 08, 2024
Trump 'An Existential Threat' To Rule Of Law, Attys Warn
January 22, 2024
HIV Drug Wholesalers' Attys Get $75M In Gilead Antitrust Case
January 08, 2024
Teva, Israeli Investors End Investor Suit Over Opioid Scandal
January 05, 2024
9th Circ. Won't Rethink FCA Disclosure Ruling Against Valeant
January 03, 2024
ACTS Retirement Data Breach Suit Settlement Gets Initial OK